ESTRO 2024 - Abstract Book

S1771

Clinical - Lung

ESTRO 2024

The strength of our study is represented by the selection of patients who constitute a homogeneous population in terms of treatments previously performed and characteristics of disease recurrence. The limitations are intrinsic to a retrospective observational study. From our results, SABR treatment appears useful to postpone second-line systemic treatment (10.2 months) in the setting of oligo-relapse mesothelioma after systemic therapy, non-radical surgical approach and radical radiotherapy.

SABR appears also well tolerated thanks to low additional toxicity. Further studies are needed to confirm our data.

Keywords: mesothelioma, reirradiation, SABR

2698

Digital Poster

Hypoxia is mitigated after carbon-ion radiotherapy in locally advanced non-small cell lung cancer

Jian Chen 1 , Jing Yi Cheng 2 , Ning Yi Ma 3 , Jing Fang Mao 1 , Kai-Liang Wu 1 , Guo-Liang Jiang 1

1 Shanghai Proton and Heavy Ion Center, Department of Radiation Oncology, Shanghai, China. 2 Shanghai Proton and Heavy Ion Center, Department of Nuclear Medicine, Shanghai, China. 3 Shanghai Proton and Heavy Ion Center, Department ofRadiation Oncology, Shanghai, China

Purpose/Objective: